Assessment and Management of Male Androgen Disorders: an Update and Signs Are Often Non-Specific and Because Related to Other Medical Conditions

Total Page:16

File Type:pdf, Size:1020Kb

Load more

CLINICAL Assessment and management of male androgen disorders: Irene Chan Mark Ng Tang Fui an update Jeffrey D Zajac Mathis Grossmann which is easily diagnosed by testicular Background examination, is not uncommon.3 Organic Male hypogonadism, caused by intrinsic pathology of the hypothalamic–pituitary– hypogonadism needs to be distinguished testicular (HPT) axis, is an under-diagnosed condition not to be missed. By from the less well-defined entity called contrast, late onset hypogonadism (LOH), due to functional suppression of the HPT late onset hypogonadism (LOH), which axis from age-related comorbidities, may be less common than previously believed. is caused by functional (and hence Objective potentially reversible) suppression of the This article outlines the aetiology, clinical features, investigation and management HPT axis due to accumulation of age- of male hypogonadism and discusses the more controversial area of LOH. related comorbidities, especially obesity. Discussion Recent data suggest that LOH is less Pathologically based hypogonadism is, after a thorough diagnostic work-up, common than previously believed and has treated with testosterone replacement therapy, unless fertility is desired. LOH with a prevalence of about 2%.4 modest reductions in testosterone levels should primarily be managed by attention to lifestyle measures, especially weight loss, and optimisation of comorbidities. In contrast to women who experience a sudden Clear treatment goals should be identified, and efficacy and safety should be drop in oestradiol levels around the time monitored according to published clinical practice guidelines. that menses ceases, the age-related drop in Keywords testosterone in men is more gradual at 0.5–2.0% men’s health; endocrine system diseases; obesity; diabetes mellitus per year from early adulthood onwards. As levels of sex hormone binding globulin (SHBG) rise with age by 1–2% per year, the decline in free testosterone level is greater and is 2–3% per Male hypogonadism is a clinical year. Most older men have testosterone levels syndrome that results from failure within the reference range and there is recent to produce physiological levels of evidence from Australia that healthy ageing alone testosterone (androgen deficiency) and may not be associated with marked decreases in a normal number of spermatozoa due testosterone levels.5 However, the age-dependent to organic pathology that disrupts one decrease in testosterone levels is accelerated or more levels of the hypothalamic– by accumulation of comorbidities, especially pituitary–testicular (HPT) axis.1 It obesity.6 Indeed, a normal testosterone level can therefore includes androgen deficiency be considered to be a sensitive biomarker of good and infertility, although both components health. can be present in isolation. The prevalence of organic hypogonadism Diagnosis of hypogonadism in Australia is about 1 in 500 men2 and The diagnosis of androgen deficiency should be general practitioners (GPs) will see made only in men with consistent symptoms several such men in their practice. There and signs, and unequivocally and repeatedly is evidence that male hypogonadism low serum testosterone levels.1 In practice this is under-diagnosed and late diagnosis diagnosis is often difficult, especially in older of, for example, Klinefelter’s syndrome, obese men with chronic disease, as symptoms REPRINTED FROM AUSTRALIAN FAMILY PHYSICIAN VOL. 43, NO. 5, MAY 2014 277 CLINICAL Assessment and management of male androgen disorders: an update and signs are often non-specific and because related to other medical conditions. In men aged symptoms and signs. Patients should be well or there is no evidence-based, universally agreed over 50 years, digital rectal examination must be medically stable, without acute decompensation pathological testosterone cut-off level.1,7 performed to exclude palpable prostate pathology of any underlying comorbidity. As testosterone before commencing testosterone replacement release is diurnal, with the highest levels in Clinical diagnosis therapy. In addition, although controversial the early morning, blood samples should be Given that hypogonadism is primarily a clinical in the general population, regular testing for taken close to 8 am. Food intake can reduce diagnosis supported by consistent biochemical prostate-specific antigen (PSA) is recommended total testosterone acutely by as much as findings, a thorough history and examination during testosterone therapy and a baseline PSA 25%, explaining the importance of a fasting are essential. Clinical assessment should be of >4 ng/ml without urological evaluation is a blood sample. There is marked variability in focused on eliciting symptoms and signs of contraindication to testosterone treatment.1 testosterone levels not only between individuals androgen deficiency and on identifying clues to but also within an individual. Therefore, repeated Biochemical diagnosis the underlying aetiology (Table 18). Signs and measurements are necessary to confirm a symptoms include incomplete or delayed sexual Of the total circulating testosterone, 60% is low testosterone level and a diagnosis of development (if hypogonadism occurs before tightly bound to SHBG, 38% is loosely bound hypogonadism should never be based on a single or during puberty), reduced libido, decreased to albumin and only 2% is free. Bioavailable testosterone level. spontaneous erections, breast discomfort, loss of testosterone refers to albumin-bound and free There is no general agreement on the body hair, reduced shaving, very small (especially testosterone. Total testosterone is the mainstay of acceptable normal range of testosterone. <5 ml) or shrinking testes, infertility, height biochemical diagnosis of androgen deficiency. Reference intervals also vary between laboratories loss, low trauma fracture, low bone mineral The initial diagnostic test in suspected because of differences in assay methods and/ density, hot flushes. It should be kept in mind androgen deficiency is measurement of fasting or reference population of men. In practice, if the that clinical features can be non-specific and morning total testosterone in men with consistent total testosterone level is 12 nmol/L or above, the patient is usually eugonadal and further testing is generally not required. If the total testosterone Table 1. Causes of androgen deficiency8 level in a man with consistent symptoms Partial/transient Primary (elevated FSH/ Secondary (low/normal and signs is less than 12 nmol/L, a repeat LH) FSH/LH) measurement of fasting morning testosterone Acute illness ACQUIRED STRUCTURAL level is suggested. Levels of 8–12 nmol/L may Chronic disease Testicular damage Tumour be considered borderline and <8 nmol/L low. If • ESRF • Trauma Surgery a testosterone level is borderline, requesting • COPD • Orchitis Radiation measurement of free testosterone may be • HIV • CTX/RTX/toxins Trauma helpful because the levels of total testosterone • T2DM Drugs Infiltration can be affected by alterations in levels of SHBG Androgen • Spironolactone • Iron overload and albumin. Men with obesity and diabetes deprivation therapy • Ketoconazole • Sarcoid commonly have a low SHBG and here a normal (GnRH agonists) • Histiocytosis free testosterone can be reassuring that such Anabolic steroids men are not, in fact, hypogonadal. In general, a repeatedly low testosterone level CONGENITAL GENETIC is more indicative of hypogonadism in younger, Klinefelter syndrome Kallmann syndrome healthier and leaner men but more difficult to Cryptorchidism 'Idiopathic' HH interpret in older obese men with chronic disease Mutations in androgen LH/FSH beta subunit mutations 6,7 biosynthesis enzymes and non-specific symptoms. LH/FSH-receptor mutations FUNCTIONAL Aetiology of hypogonadism Myotonic dystrophy Hyperprolactinaemia Once the low testosterone value has been Morbid obesity confirmed on repeated morning measurements Cushing’s syndrome in patients with consistent symptoms and Alcohol excess* signs, luteinizing hormone (LH) and follicle COPD, chronic obstructive pulmonary disease; CTX, chemotherapy; ESRF, end stage stimulating hormone (FSH) values should be renal disease; RTX, radiotherapy; HH, hypogonadotropic hypogonadism; obtained to further distinguish between primary T2DM, type 2 diabetes mellitus or secondary hypogonadism (Table 1). Elevated *Alcohol excess typically causes mixed (combined primary and secondary) hypogonadism. LH and FSH values indicate primary (testicular) 278 REPRINTED FROM AUSTRALIAN FAMILY PHYSICIAN VOL. 43, NO. 5, MAY 2014 Assessment and management of male androgen disorders: an update CLINICAL hypogonadism, whereas low or importantly even for example due to a microprolactinoma, the Haemochromatosis can be ruled out by measuring inappropriately ‘normal’ LH and FSH values may hypogonadism will respond to, and should be iron levels and determining the fasting transferrin indicate secondary (pituitary–hypothalamic) treated by, normalising the prolactin level rather saturation. Biochemical assessment of pituitary hypogonadism. Combined primary and secondary than by testosterone therapy. (dys-)function may be necessary, and pituitary hypogonadism have variable gonadotropin levels, In the work-up for secondary hypogonadism, imaging may need to be considered. Given that depending on whether primary or secondary it is very important not to miss pituitary functional hypogonadism due to comorbidities hypogonadism predominates. or hypothalamic pathology, which can presents with
Recommended publications
  • Sex Hormones Related Ocular Dryness in Breast Cancer Women

    Sex Hormones Related Ocular Dryness in Breast Cancer Women

    Journal of Clinical Medicine Review Sex Hormones Related Ocular Dryness in Breast Cancer Women Antonella Grasso 1, Antonio Di Zazzo 2,* , Giuseppe Giannaccare 3 , Jaemyoung Sung 4 , Takenori Inomata 4 , Kendrick Co Shih 5 , Alessandra Micera 6, Daniele Gaudenzi 2, Sara Spelta 2 , Maria Angela Romeo 7, Paolo Orsaria 1, Marco Coassin 2 and Vittorio Altomare 1 1 Breast Unit, University Campus Bio-Medico, 00128 Rome, Italy; [email protected] (A.G.); [email protected] (P.O.); [email protected] (V.A.) 2 Ophthalmology Operative Complex Unit, University Campus Bio-Medico, 00128 Rome, Italy; [email protected] (D.G.); [email protected] (S.S.); [email protected] (M.C.) 3 Department of Ophthalmology, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy; [email protected] 4 Department of Ophthalmology, School of Medicine, Juntendo University, 1130033 Tokyo, Japan; [email protected] (J.S.); [email protected] (T.I.) 5 Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong; [email protected] 6 Research and Development Laboratory for Biochemical, Molecular and Cellular Applications in Ophthalmological Sciences, IRCCS–Fondazione Bietti, 00198 Rome, Italy; [email protected] 7 School of Medicine, Humanitas University, 20089 Milan, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-06225418893; Fax: +39-9622541456 Abstract: Background: Dry eye syndrome (DES) is strictly connected to systemic and topical sex hor- mones. Breast cancer treatment, the subsequent hormonal therapy, the subsequent hyperandrogenism and the early sudden menopause, may be responsible for ocular surface system failure and its clinical Citation: Grasso, A.; Di Zazzo, A.; manifestation as dry eye disease.
  • Androgens Utilization Management Criteria

    Androgens Utilization Management Criteria

    ANDROGENS UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: Androgens Generic (Brand) NAMES: • Fluoxymesterone (Androxy®) • Methyltestosterone (Android®, Methitest®, Testred®) • Testosterone, topical A. Androderm®, Androgel® - Preferred topical testosterone ® ® ® ™ B. Testim , Fortesta , Axiron , Bio-T-Gel • Testosterone, buccal (Striant®) • Testosterone cypionate (e.g., Depo-Testosterone®) • Testosterone enanthate (e.g., Delatestryl®) FDA-APPROVED INDICATIONS: Replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. Hypogonadotropic hypogonadism (congenital or acquired): Idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty: To stimulate puberty in carefully selected males with clearly delayed puberty. Metastatic mammary cancer in women: Used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal COVERAGE AUTHORIZATION CRITERIA for the androgen products listed above: 1. Being used for ONE of the following: a. Males for the treatment of hypogonadism (low testosterone): i. patient has symptoms of androgen deficiency AND ii. has a baseline (pre-treatment) morning serum total testosterone level of less than or equal to 300 ng/dL or a serum total testosterone level that is below the testing laboratory’s lower limit of the normal range OR iii. baseline morning serum free testosterone level, measured by the equilibrium dialysis method, of less than or equal to 50 pg/ml or a free serum testosterone level that is below the testing laboratory’s lower limit of the normal range, OR b.
  • Background Briefing Document from the Consortium of Sponsors for The

    Background Briefing Document from the Consortium of Sponsors for The

    BRIEFING BOOK FOR Pediatric Advisory Committee (PAC) Prepared by Alan Rogol, M.D., Ph.D. Prepared for Consortium of Sponsors Meeting Date: April 8th, 2019 TABLE OF CONTENTS LIST OF FIGURES ................................................... ERROR! BOOKMARK NOT DEFINED. LIST OF TABLES ...........................................................................................................................4 1. INTRODUCTION AND BACKGROUND FOR THE MEETING .............................6 1.1. INDICATION AND USAGE .......................................................................................6 2. SPONSOR CONSORTIUM PARTICIPANTS ............................................................6 2.1. TIMELINE FOR SPONSOR ENGAGEMENT FOR PEDIATRIC ADVISORY COMMITTEE (PAC): ............................................................................6 3. BACKGROUND AND RATIONALE .........................................................................7 3.1. INTRODUCTION ........................................................................................................7 3.2. PHYSICAL CHANGES OF PUBERTY ......................................................................7 3.2.1. Boys ..............................................................................................................................7 3.2.2. Growth and Pubertal Development ..............................................................................8 3.3. AGE AT ONSET OF PUBERTY.................................................................................9 3.4.
  • Serum Androgen Profiles in Women with Premature Ovarian Insufficiency: a Systematic Review and Meta-Analysis

    Serum Androgen Profiles in Women with Premature Ovarian Insufficiency: a Systematic Review and Meta-Analysis

    Menopause: The Journal of The North American Menopause Society Vol. 26, No. 1, pp. 78-93 DOI: 10.1097/GME.0000000000001161 ß 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The North American Menopause Society. Serum androgen profiles in women with premature ovarian insufficiency: a systematic review and meta-analysis Midhun Soman, MS,1 Li-Cong Huang, MD,1 Wen-Hui Cai, MS,1 Jun-Bi Xu, MS,1 Jun-Yao Chen, MD,1 Ren-Ke He, MS,1 Heng-Chao Ruan, MS,1,2,3 Xiang-Rong Xu, MD,1,2,3 Zhi-Da Qian, MD,1,2,3,4 and Xiao-Ming Zhu, MD, PhD1,2,3 Abstract Objective: This meta-analysis aims to investigate serum androgen profiles (testosterone, dehydroepiandroster- one sulfate, androstenedione, and sex hormone-binding globulin) in women with premature ovarian failure and to establish if there is evidence of diminished androgen levels in these women. Methods: Various Internet sources of PubMed, Cochrane library, and Medline were searched systematically until February, 2018. Out of a pool of 2,461 studies, after applying the inclusion/exclusion criterion, 14, 8, 10, and 9 studies were chosen for testosterone, dehydroepiandrosterone sulfate, androstenedione, and sex hormone-binding globulin, respectively, for this meta-analysis. The effect measure was the standardized mean difference with 95% confidence interval (95% CI) in a random-effects model. Results: The testosterone concentrations in premature ovarian insufficiency were compared with fertile controls: stamdard mean difference (IV, random, 95% CI) À0.73 [À0.99, À0.46], P value < 0.05. The dehydroepiandrosterone sulfate concentrations in premature ovarian insufficiency compared to fertile controls: standard mean difference (IV, random, 95% CI) À0.65 [À0.92, À0.37], P value < 0.05.
  • Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’S Time to Sound the Alarm

    Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’S Time to Sound the Alarm

    Review Article Health promotion, disease prevention, and lifestyle pISSN: 2287-4208 / eISSN: 2287-4690 World J Mens Health 2020 Jul 38(3): 323-337 https://doi.org/10.5534/wjmh.200012 Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’s Time to Sound the Alarm Abdulmaged M. Traish Department of Urology, Boston University School of Medicine, Boston, MA, USA 5α-dihydrotestosterone (5α-DHT) is the most potent natural androgen. 5α-DHT elicits a multitude of physiological actions, in a host of tissues, including prostate, seminal vesicles, hair follicles, skin, kidney, and lacrimal and meibomian glands. How- ever, the physiological role of 5α-DHT in human physiology, remains questionable and, at best, poorly appreciated. Recent emerging literature supports a role for 5α-DHT in the physiological function of liver, pancreatic β-cell function and survival, ocular function and prevention of dry eye disease and kidney physiological function. Thus, inhibition of 5α-reductases with finasteride or dutasteride to reduce 5α-DHT biosynthesis in the course of treatment of benign prostatic hyperplasia (BPH) or male pattern hair loss, known as androgenetic alopecia (AGA) my induces a novel form of tissue specific androgen deficien- cy and contributes to a host of pathophysiological conditions, that are yet to be fully recognized. Here, we advance the con- cept that blockade of 5α-reductases by finasteride or dutasteride in a mechanism-based, irreversible, inhabitation of 5α-DHT biosynthesis results in a novel state of androgen deficiency, independent of circulating testosterone levels. Finasteride and dutasteride are frequently prescribed for long-term treatment of lower urinary tract symptoms in men with BPH and in men with AGA.
  • EAU Pocket Guidelines on Male Hypogonadism 2013

    EAU Pocket Guidelines on Male Hypogonadism 2013

    GUIDELINES ON MALE HYPOGONADISM G.R. Dohle (chair), S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by andro- gen deficiency. It may adversely affect multiple organ func- tions and quality of life. Androgens play a crucial role in the development and maintenance of male reproductive and sexual functions. Low levels of circulating androgens can cause disturbances in male sexual development, resulting in congenital abnormalities of the male reproductive tract. Later in life, this may cause reduced fertility, sexual dysfunc- tion, decreased muscle formation and bone mineralisation, disturbances of fat metabolism, and cognitive dysfunction. Testosterone levels decrease as a process of ageing: signs and symptoms caused by this decline can be considered a normal part of ageing. However, low testosterone levels are also associated with several chronic diseases, and sympto- matic patients may benefit from testosterone treatment. Androgen deficiency increases with age; an annual decline in circulating testosterone of 0.4-2.0% has been reported. In middle-aged men, the incidence was found to be 6%. It is more prevalent in older men, in men with obesity, those with co-morbidities, and in men with a poor health status. Aetiology and forms Male hypogonadism can be classified in 4 forms: 1. Primary forms caused by testicular insufficiency. 2. Secondary forms caused by hypothalamic-pituitary dysfunction. 164 Male Hypogonadism 3. Late onset hypogonadism. 4. Male hypogonadism due to androgen receptor insensitivity. The main causes of these different forms of hypogonadism are highlighted in Table 1. The type of hypogonadism has to be differentiated, as this has implications for patient evaluation and treatment and enables identification of patients with associated health problems.
  • Androgen Deficiency Guideline Results

    Androgen Deficiency Guideline Results

    Improving testosterone testing in people living with HIV V. Kopanitsa1, S. Flavell2, J. Ashby2, I. Ghosh2, S. Candfield2, U. Srirangalingm2, L. Waters2 1. University College London (UCL) Medical School; 2. Central and North West London NHS Foundation Trust Introduction Aims Symptomatic testosterone (T) deficiency is more common in people living 1. Review local practice in the clinic with HIV (PLWH) than the HIV negative male population; despite this, 2. Introduce a local guideline with investigation and management pathways specific guidelines are lacking. [1,2] for assessing T deficiency in PLWH with a view to earlier diagnosis and more efficient use of resources Patients with T deficiency can experience a number of symptoms such as 3. Re-audit after guideline implementation erectile dysfunction (ED) and reduced libido, and also less specific symptoms including low mood, fatigue and reduced muscle mass [1,2,3]. Total T (free and protein-bound) is the most common measurement reported Methods when a testosterone test is requested. In PLWH, raised sex hormone 1. A retrospective notes review was completed on all patients who had a T binding globulin (SHBG) levels are common, and so calculation of free T test between 01/06/17 and 30/11/17, and 17/09/18 to 14/12/18, before more accurately reflects T levels in this group. SHBG and Albumin tests are and after guideline implementation, respectively. The following outcomes needed for this for this calculation, which is done via an online calculator [4]. from the guideline were assessed: T also varies by circadian rhythm and should be measured at peak time in 2.
  • Hypogonadism in Adolescence 173:1 R15–R24 Review

    Hypogonadism in Adolescence 173:1 R15–R24 Review

    A A Dwyer and others Hypogonadism in adolescence 173:1 R15–R24 Review TRANSITION IN ENDOCRINOLOGY Hypogonadism in adolescence Andrew A Dwyer1,2, Franziska Phan-Hug1,3, Michael Hauschild1,3, Eglantine Elowe-Gruau1,3 and Nelly Pitteloud1,2,3,4 1Center for Endocrinology and Metabolism in Young Adults (CEMjA), 2Endocrinology, Diabetes and Metabolism Correspondence Service and 3Division of Pediatric Endocrinology Diabetology and Obesity, Department of Pediatric Medicine and should be addressed Surgery, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland and to N Pitteloud 4Department of Physiology, Faculty of Biology and Medicine, University of Lausanne, Rue du Bugnon 7, Email 1005 Lausanne, Switzerland [email protected] Abstract Puberty is a remarkable developmental process with the activation of the hypothalamic–pituitary–gonadal axis culminating in reproductive capacity. It is accompanied by cognitive, psychological, emotional, and sociocultural changes. There is wide variation in the timing of pubertal onset, and this process is affected by genetic and environmental influences. Disrupted puberty (delayed or absent) leading to hypogonadism may be caused by congenital or acquired etiologies and can have significant impact on both physical and psychosocial well-being. While adolescence is a time of growing autonomy and independence, it is also a time of vulnerability and thus, the impact of hypogonadism can have lasting effects. This review highlights the various forms of hypogonadism in adolescence and the clinical challenges in differentiating normal variants of puberty from pathological states. In addition, hormonal treatment, concerns regarding fertility, emotional support, and effective transition to adult care are discussed. European Journal of Endocrinology (2015) 173, R15–R24 European Journal of Endocrinology Introduction Adolescence is generally defined as the transitional phase (FSH)) (1, 2).
  • Androgen Deficiency Diagnosis and Management

    Androgen Deficiency Diagnosis and Management

    4 Clinical Summary Guide Androgen Deficiency Diagnosis and management Androgen deficiency (AD) * Pituitary disease, thalassaemia, haemochromatosis. • Androgen deficiency is common, affecting 1 in 200 men under ** AD is an uncommon cause of ED. However, all men presenting 60 years with ED should be assessed for AD • The clinical presentation may be subtle and its diagnosis Examination and assessment of clinical features of AD overlooked unless actively considered Pre-pubertal onset – Infancy The GP’s role • Micropenis • GPs are typically the first point of contact for men with • Small testes symptoms of AD • The GP’s role in the management of AD includes clinical Peri-pubertal onset – Adolescence assessment, laboratory investigations, treatment, referral • Late/incomplete sexual and somatic maturation and follow-up • Small testes • Note that it in 2015 the PBS criteria for testosterone • Failure of enlargement of penis and skin of scrotum becoming prescribing changed; the patient must be referred for a thickened/pigmented consultation with an endocrinologist, urologist or member of • Failure of growth of the larynx the Australasian Chapter of Sexual Health Medicine to be eligible for PBS-subsidised testosterone prescriptions • Poor facial, body and pubic hair • Gynecomastia Androgen deficiency and the ageing male • Poor muscle development • Ageing may be associated with a 1% decline per year in serum Post-pubertal onset – Adult total testosterone starting in the late 30s • Regression of some features of virilisation • However, men who
  • Male Hypogonadism: Quick Reference for Residents

    Male Hypogonadism: Quick Reference for Residents

    Male hypogonadism: Quick Reference for Residents Soe Naing, MD, MRCP(UK), FACE Endocrinologist Associate Clinical Professor of Medicine Director of Division of Endocrinology Medical Director of Community Diabetes Care Center UCSF-Fresno Medical Education Program Version: SN/8-21-2017 Male hypogonadism From Harrison's Principles of Internal Medicine, 19e and Up-To-Date accessed on 8-21-2017 Testosterone is FDA-approved as replacement therapy only for men who have low testosterone levels due to disorders of the testicles, pituitary gland, or brain that cause hypogonadism. Examples of these disorders include primary hypogonadism because of genetic problems, or damage from chemotherapy or infection (mump orchitis). However, FDA has become aware that testosterone is being used extensively in attempts to relieve symptoms in men who have low testosterone for no apparent reason other than aging. Some studies reported an increased risk of heart attack, stroke, or death associated with testosterone treatment, while others did not. FDA cautions that prescription testosterone products are approved only for men who have low testosterone levels caused by a medical condition. http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm 2 Hypothalamic-pituitary-testicular axis Schematic representation of the hypothalamic-pituitary- testicular axis. GnRH from the hypothalamus stimulates the gonadotroph cells of the pituitary to secrete LH and FSH. LH stimulates the Leydig cells of the testes to secrete testosterone. The high concentration of testosterone within the testes is essential for spermatogenesis within the seminiferous tubules. FSH stimulates the Sertoli cells within the seminiferous tubules to make inhibin B, which also stimulates spermatogenesis. Testosterone inhibits GnRH secretion, and inhibin B inhibits FSH secretion.
  • Management of Women with Premature Ovarian Insufficiency

    Management of Women with Premature Ovarian Insufficiency

    Management of women with premature ovarian insufficiency Guideline of the European Society of Human Reproduction and Embryology POI Guideline Development Group December 2015 1 Disclaimer The European Society of Human Reproduction and Embryology (hereinafter referred to as 'ESHRE') developed the current clinical practice guideline, to provide clinical recommendations to improve the quality of healthcare delivery within the European field of human reproduction and embryology. This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. The aim of clinical practice guidelines is to aid healthcare professionals in everyday clinical decisions about appropriate and effective care of their patients. However, adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not override the healthcare professional's clinical judgment in diagnosis and treatment of particular patients. Ultimately, healthcare professionals must make their own clinical decisions on a case-by-case basis, using their clinical judgment, knowledge, and expertise, and taking into account the condition, circumstances, and wishes of the individual patient, in consultation with that patient and/or the guardian or carer. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. ESHRE shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein.
  • TUE Physician Guidelines 1. Medical Condition Hypogonadism in Men Is

    TUE Physician Guidelines 1. Medical Condition Hypogonadism in Men Is

    TUE Physician Guidelines MALE HYPOGONADISM 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (testosterone deficiency) and in some instances normal number of spermatozoa (infertility) due to disruption of one or more levels of the hypothalamic-pituitary-testicular axis. The two distinct yet interdependent testicular functions, steroidogenesis (testosterone production) and spermatogenesis can fail independently. Testosterone deficiency is the focus of this document. 2. Diagnosis A. Etiology Hypogonadism may be primary, due to a problem with the testes, or secondary, due to a problem with the hypothalamus or pituitary gland or combined primary and secondary. The etiology of testosterone deficiency may be organic, in which there is a pathological structural or congenital defect within the hypothalamic-pituitary- testicular axis. Hypogonadism may be functional in which there is no observable pathological change in the structures within the hypothalamic-pituitary-testicular axis. Hypogonadism may be functional in which there is no observable pathological change in the structures within the hypothalamic-pituitary-testicular axis. Organic hypogonadism is usually long-lasting or permanent while functional hypogonadism is potentially reversible. TUE should only be approved for hypogonadism that has an organic etiology. TUE should not be approved for androgen deficiency due to functional disorder. TUE for androgen deficiency should not be approved for females. Organic causes of hypogonadism (See Appendix A for a more detailed list) 1. Organic primary hypogonadism may be due to: a. Genetic abnormalities b. Developmental abnormalities c. Testicular trauma, bilateral orchiectomy, testicular torsion d. Orchitis e. Radiation treatment or chemotherapy.